Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience
- 1 February 2008
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 7 (1) , 75-82
- https://doi.org/10.1586/14760584.7.1.75
Abstract
Annual use of influenza vaccines represents the largest vaccine campaign conducted in the USA. Recent expansions in influenza vaccine recommendations suggest a move toward 'universal' vaccination strategies. Although a great deal of safety data has been accumulated, concerns remain regarding rare, serious adverse events following immunization. A proven association between the 1976-1977 swine influenza vaccine and Guillain-Barré syndrome halted that particular national vaccination campaign. Recently, annual influenza vaccines have been associated with novel adverse events, for example, oculorespiratory syndrome in Canada. Any vaccine used against an influenza strain of pandemic potential will have an incompletely described safety profile. Thus, the challenge of influenza vaccine safety is to detect new safety concerns that may arise during seasonal campaigns, while preparing vaccine safety systems for the timely detection of adverse events in the setting of a pandemic.Keywords
This publication has 35 references indexed in Scilit:
- 'Pandemic Vaccine' Appears to Protect Only at High DosesScience, 2005
- Race against timeNature, 2005
- Vaccine Cell Substrates 2004Expert Review of Vaccines, 2004
- Guillain-Barré Syndrome Following Influenza VaccinationJAMA, 2004
- Myopericarditis following Smallpox VaccinationAmerican Journal of Epidemiology, 2004
- From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenzaNature Reviews Microbiology, 2004
- Risk of Anaphylaxis After Vaccination of Children and AdolescentsPediatrics, 2003
- The science of evaluation of adverse events associated with vaccinationSeminars in Pediatric Infectious Diseases, 2002
- Detection of adverse events: what are the current sensitivity limits during clinical development?Vaccine, 2001
- The Guillain–Barré Syndrome and the 1992–1993 and 1993–1994 Influenza VaccinesNew England Journal of Medicine, 1998